Revvity Inc (RVTY)

Apr 21, 2025

Earnings Preview: Revvity (RVTY) Q1 Earnings Expected to Decline - Yahoo Finance

Apr 21, 2025

Apr 21, 2025

Revvity (RVTY) Price Target Cut by Baird Ahead of Q1 Results | RVTY Stock News - GuruFocus

Apr 21, 2025

Apr 16, 2025

Bernstein Adjusts Price Target on Revvity to $120 From $140, Maintains Market Perform Rating - marketscreener.com

Apr 16, 2025

Apr 16, 2025

Revvity price target lowered to $120 from $140 at Bernstein - TipRanks

Apr 16, 2025

Apr 16, 2025

Lab equipment giant ensnared in sprawling $300M fraud case over failed testing tools - Green Market Report

Apr 16, 2025

Apr 16, 2025

Revvity (RVTY) Faces Price Target Cut Amid Funding Concerns | RV - GuruFocus

Apr 16, 2025

Apr 15, 2025

Ex-Dividend Reminder: Revvity, Dime Community Bancshares and First Busey - Nasdaq

Apr 15, 2025

Apr 15, 2025

What Is Revvity, Inc.'s (NYSE:RVTY) Share Price Doing? - Yahoo Finance

Apr 15, 2025

Apr 15, 2025

BofA Reduces Revvity (RVTY) Price Target Amid Policy Challenges - GuruFocus

Apr 15, 2025

Apr 14, 2025

BofA Securities Cuts Price Target on Revvity to $116 From $143, Maintains Buy Rating - MarketScreener

Apr 14, 2025

Apr 14, 2025

BofA Reduces Revvity (RVTY) Price Target Amid Policy Challenges | RVTY Stock News - GuruFocus

Apr 14, 2025

Apr 11, 2025

KeyBanc Lowers Price Target on Revvity to $135 From $145 - MarketScreener

Apr 11, 2025

Apr 11, 2025

Barclays Adjusts Revvity (RVTY) Price Target Ahead of Q1 Earnings | RVTY Stock News - GuruFocus

Apr 11, 2025

Apr 10, 2025

Barclays Adjusts Price Target on Revvity to $110 From $140 - MarketScreener

Apr 10, 2025

Apr 09, 2025

KeyBanc maintains Overweight rating on Revvity stock at $145 target - Investing.com Australia

Apr 09, 2025

Apr 09, 2025

KeyBanc maintains Overweight rating on Revvity stock at $145 target By Investing.com - Investing.com South Africa

Apr 09, 2025

Apr 09, 2025

KeyBanc Adjusts Price Target on Revvity to $145 From $135, Keeps Overweight Rating - MarketScreener

Apr 09, 2025

Apr 07, 2025

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price - simplywall.st

Apr 07, 2025

Apr 07, 2025

Revvity Signals Software Unveils Unified Data Platform To Accelerate Drug Discovery - Technology Networks

Apr 07, 2025

Apr 07, 2025

Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test - Technology Networks

Apr 07, 2025

Apr 03, 2025

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now - MSN

Apr 03, 2025

Apr 03, 2025

Revvity Q1 2025 Earnings Preview: CEO and CFO to Detail Financial Performance - Stock Titan

Apr 03, 2025

Apr 03, 2025

FDA approves Revvity’s Auto-Pure platform and tuberculosis test combo - Yahoo

Apr 03, 2025

Apr 02, 2025

Revvity (RVTY) Gains FDA Approval for Automated TB Test - GuruFocus

Apr 02, 2025

Apr 02, 2025

FDA greenlights Revvity’s TB diagnostic platform By Investing.com - Investing.com South Africa

Apr 02, 2025

Apr 02, 2025

What's Going On With Revvity Stock Today? - Benzinga

Apr 02, 2025

Apr 02, 2025

(RVTY) Investment Analysis - news.stocktradersdaily.com

Apr 02, 2025

Apr 02, 2025

Evercore ISI Adjusts Revvity Price Target to $125 From $138, Maintains Outperform Rating - MarketScreener

Apr 02, 2025

Apr 02, 2025

FDA Approves Revvity’s Improved Automated Latent Tuberculosis Test - Medical Product Outsourcing

Apr 02, 2025

Apr 02, 2025

Revvity gets FDA nod for its automated tuberculosis test (RVTY:NYSE) - Seeking Alpha

Apr 02, 2025

Apr 02, 2025

Revvity Says FDA Approves Auto-Pure 2400 Liquid Handler for Tuberculosis Test - marketscreener.com

Apr 02, 2025

Apr 02, 2025

FDA greenlights Revvity’s TB diagnostic platform - Investing.com India

Apr 02, 2025

Apr 02, 2025

Revvity Secures FDA Approval For Improved Automated Latent Tuberculosis Test - MarketScreener

Apr 02, 2025

Apr 02, 2025

Game-Changing TB Test: Revvity's New FDA-Approved System Cuts Testing Time by 70% - Stock Titan

Apr 02, 2025

Apr 02, 2025

Pictet Asset Management Holding SA Has $125.17 Million Holdings in Revvity, Inc. (NYSE:RVTY) - MarketBeat

Apr 02, 2025

Mar 31, 2025

Is Revvity Stock Underperforming the Nasdaq? - MSN

Mar 31, 2025

Mar 28, 2025

High Content Screening/Imaging Technology Analysis and Global Market Forecasts 2025-2029 with Danaher, Revvity, Thermo Fischer Scientific, Agilent Technologies and Yokogawa LeadingResearchAndMarkets.com - Bluefield Daily Telegraph

Mar 28, 2025

Mar 28, 2025

Is Revvity Stock Underperforming The Nasdaq? - Barchart.com

Mar 28, 2025

Mar 27, 2025

Is Revvity Gaining or Losing Market Support? - Benzinga

Mar 27, 2025

Mar 27, 2025

Revvity Expands Alliance With Genomics England To Drive Research Into Newborn Genomic Sequencing in England - Technology Networks

Mar 27, 2025

Mar 25, 2025

Revvity Stock Tumbles Despite Expanding Genomics England Alliance - MSN

Mar 25, 2025

Mar 25, 2025

The total return for Revvity (NYSE:RVTY) investors has risen faster than earnings growth over the last five years - Yahoo Finance

Mar 25, 2025

Mar 21, 2025

Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England - BioSpace

Mar 21, 2025

Mar 20, 2025

Revvity Expands Alliance with Genomics England -March 20, 2025 at 02:10 pm EDT - MarketScreener

Mar 20, 2025

Mar 20, 2025

Massive Breakthrough: Revvity's 100K Newborn Genetic Screening Program Targets 200 Rare Diseases - StockTitan

Mar 20, 2025

Mar 20, 2025

May 16th Options Now Available For Revvity (RVTY) - Nasdaq

Mar 20, 2025

Mar 20, 2025

Should You Think About Buying Revvity, Inc. (NYSE:RVTY) Now? - Simply Wall St

Mar 20, 2025

Mar 19, 2025

Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Mar 19, 2025